SCHEMBL1642609

SCHEMBL1642609

CCCC(=O)NCC1=CCC(C)(C(N)=O)C=C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
EPHX2 P34913 2/20 0.33
CASP2 P42575 1/20 0.33
LMNA P02545 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HDAC9 Q9UKV0 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32
RECQL P46063 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31381391 0.64
SCHEMBL6824244 0.58 CYP3A4 (0.66) CYP3A4CYP2C19L3MBTL1EPHX2LMNA
SCHEMBL9938968 0.57 CYP3A4 (0.51) CYP3A4CYP2C19L3MBTL1EPHX2CASP2
SCHEMBL18134836 0.57 CYP3A4 (0.65) CYP3A4CYP2C19L3MBTL1EPHX2LMNA
SCHEMBL770934 0.57 CYP3A4 (0.87) CYP3A4CYP2C19L3MBTL1EPHX2RECQL
SCHEMBL18536403 0.57 MEN1 (0.42) EPHX2LMNAMEN1GAAHPGD
SCHEMBL7771322 0.57 CTSD (0.52) CYP3A4CYP2C19L3MBTL1CASP2LMNA
SCHEMBL28237509 0.56 FAAH (0.65) CYP3A4CYP2C19L3MBTL1EPHX2LMNA
SCHEMBL2926521 0.56 ALDH1A1 (0.69) CYP3A4CYP2C19L3MBTL1KDM4EMEN1
SCHEMBL17335992 0.56 CYP3A4 (0.63) CYP3A4CYP2C19L3MBTL1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255062-B2 Fatty acid derivatives for oral administration endowed with high palatability RHEA INNOVATIONS S.R.L. (IT) 2016-02-09 US claimed
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY RHEA INNOVATIONS S.R.L. (IT) 2011-04-28 US claimed
US-9255062-B2 Fatty acid derivatives for oral administration endowed with high palatability RHEA INNOVATIONS S.R.L. (IT) 2016-02-09 US disclosed
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY RHEA INNOVATIONS S.R.L. (IT) 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098319-A1 FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY FABP2, FFAR2, VIP CYP3A4 679/4885CYP2C19 938/4885L3MBTL1 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.